Serious Event

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Serious Event

Serious Adverse Events (SAEs) are adverse events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability/incapacity, or are congenital anomalies/birth defects. Each serious event is categorized by term, organ system, assessment type, and source vocabulary to provide standardized reporting across clinical trials.

Serious Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Serious Event

Study -> Results Section -> Adverse Events Module -> Serious Event -> Serious Event Stats

Serious Event

Ignite Creation Date: 2025-12-24 @ 6:56 PM
Ignite Modification Date: 2025-12-25 @ 4:29 PM
NCT ID: NCT03284957
Term: Retinal Detachment
Organ System: Eye disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDra 27.1
Notes: None
Study: NCT03284957
Study Brief: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Serious Event Stats (If Any):

Serious Event Stats

Group ID # Events # Affected # At Risk View
EG000 0 0 3 View
EG001 0 0 3 View
EG002 0 0 4 View
EG003 0 0 3 View
EG004 0 0 3 View
EG005 0 0 6 View
EG006 1 1 49 View
EG007 0 0 9 View
EG008 0 0 6 View
EG009 0 0 30 View
EG010 0 0 8 View
EG011 0 0 3 View
EG012 0 0 3 View
EG013 0 0 1 View
EG014 0 0 3 View
EG015 0 0 2 View